Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2011

View Archived Issues

BMS-650032 and BMS-790052 evaluated separately and combined in hepatitis C

Rivaroxaban shows promise in prevention of VTE in medically ill patients

Galderma researchers present novel series of ADAM 17 inhibitors

Senju Pharma claims new polypeptides for corneal epithelial disorders

Novel neuropeptide Y2 receptor agonists presented by Novartis

Chemical structures of LX-1031 and ASP-1941 disclosed at American Chemical Society meeting

Protein NDRG2 may serve as biomarker to predict clinical outcome of CCRCC

Taiho Pharma's new angiogenesis inhibitor TAS-115 is safe and active in models of cancer

Preliminary phase II data disclosed on ACE-031 in Duchenne's muscular dystrophy

New modulators presented of alpha-adrenoceptors, histamine, dopamine and serotonin receptors

Corcept Therapeutics submits NDA for Corlux in Cushing's syndrome

Amira Pharma patents new arachidonate 5-lipoxygenase inhibitors

VEGF Trap-Eye BLA gets FDA priority review for treatment of wet AMD

PharmaGap reports preclinical data on lead cancer drug, GAP-107B8

Chelsea Therapeutics updates Northera NDA filing strategy in NOH

CHMP recommends amendments to Pandemrix's product information

FDA requires news studies of LABA-containing drugs

National Cancer Institute begins phase II study of TRC-105 in urothelial carcinoma

Novartis begins phase II trial of BCT-197 in COPD

Pivotal phase III GLOW1 study of NVA-237 in COPD meets primary endpoint

Teijin Pharma signs distribution agreements for febuxostat in multiple regions worldwide

First patient treated in phase III CIRCUS study of NeuroVive's CicloMulsion

Pluristem Therapeutics reports follow-up data from phase I PLX-PAD trials

Inovio, Transgene and ChronTech to collaborate on novel HCV vaccination strategy

Evotec acquires Kinaxo Biotechnologies

Nabriva's BC-3781 shows comparable efficacy to vancomycin in skin and skin structure infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...